Your browser is no longer supported. Please, upgrade your browser.
Settings
UTHR United Therapeutics Corporation daily Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E50.33 EPS (ttm)3.38 Insider Own0.10% Shs Outstand46.22M Perf Week-4.77%
Market Cap7.86B Forward P/E14.15 EPS next Y12.02 Insider Trans-94.09% Shs Float45.56M Perf Month-7.54%
Income185.90M PEG2.57 EPS next Q2.32 Inst Own- Short Float14.67% Perf Quarter-2.64%
Sales1.33B P/S5.93 EPS this Y91.50% Inst Trans0.08% Short Ratio10.13 Perf Half Y31.37%
Book/sh23.81 P/B7.14 EPS next Y62.76% ROA9.50% Target Price169.93 Perf Year86.12%
Cash/sh14.21 P/C11.97 EPS next 5Y19.57% ROE15.50% 52W Range86.04 - 190.29 Perf YTD31.37%
Dividend- P/FCF24.50 EPS past 5Y79.20% ROI25.40% 52W High-10.37% Beta1.55
Dividend %- Quick Ratio1.40 Sales past 5Y29.10% Gross Margin91.20% 52W Low98.22% ATR4.98
Employees740 Current Ratio1.50 Sales Q/Q13.20% Oper. Margin23.20% RSI (14)39.16 Volatility3.14% 2.72%
OptionableYes Debt/Eq0.10 EPS Q/Q-114.80% Profit Margin14.00% Rel Volume0.67 Prev Close170.11
ShortableYes LT Debt/Eq0.00 EarningsJul 28 BMO Payout0.00% Avg Volume659.83K Price170.55
Recom2.30 SMA20-5.79% SMA50-4.46% SMA20011.67% Volume410,393 Change0.26%
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Dec-31-13Reiterated Argus Buy $120 → $130
Dec-23-13Upgrade Ladenburg Thalmann Neutral → Buy $138
Dec-02-13Reiterated Argus Buy $85 → $110
Aug-05-13Reiterated Argus Buy $75 → $85
Jul-30-13Downgrade Standpoint Research Buy → Hold
Jun-20-13Upgrade Standpoint Research Hold → Buy
May-15-13Downgrade Standpoint Research Buy → Hold
Mar-25-13Reiterated Ladenburg Thalmann Buy $69 → $63
Jun-29-15 03:53PM  Why Jazz Pharmaceuticals Is Winning
06:06AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc
06:00AM  Dean Judy D. Olian Joins the United Therapeutics Corporation Board of Directors PR Newswire
Jun-26-15 04:11PM  This entrepreneur wants to fix the transplant shortage by recycling human organs
Jun-24-15 02:52PM  Dow Slips Back Below 18,000; GM Plunges; Autohome Up at Investor's Business Daily
Jun-22-15 06:28PM  IBD Market Wrap - 06/22/15
Jun-18-15 03:02PM  Jacksonville lung transplant center will be the first of its kind in the U.S., bringing more jobs and capital investment at bizjournals.com
09:10AM  KYTH up 26.7% over past day, pushes Palo Alto Investors Forward
Jun-17-15 03:00PM  Silver Spring biotech faces patent challenge for major revenue drug at bizjournals.com
12:01PM  Bioscience firm planning major expansion in Silver Spring at bizjournals.com
Jun-16-15 04:55PM  United Therapeutics Faces Patent Challenge for Tyvaso - Analyst Blog
Jun-15-15 04:25PM  UTHR CEO: Future of biotech
09:16AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
09:00AM  United Therapeutics Corporation Receives Paragraph IV Notice Letter for Tyvaso PR Newswire
Jun-01-15 04:00PM  United Therapeutics Corporation - ZER Reports
May-29-15 06:00AM  United Therapeutics Corporation To Present At The Jefferies 2015 Global Healthcare Conference PR Newswire
May-20-15 06:00AM  Jim Cramer's Top Takeaways: United Therapeutics, American Airlines, Wix.com at TheStreet
May-19-15 07:58PM  Jim Cramer's 'Mad Money' Recap: Looking for Profitable Retailers? Follow the Clues at TheStreet
07:26PM  Cramer Remix: It went to $500 from $5 & isn't done at CNBC
06:46PM  Highest paid female CEO: Race to save my daughter at CNBC
May-05-15 01:40PM  Apple's Angela Ahrendts Is Nation's Best-Paid Female Executive
May-04-15 05:43PM  Live forever? Maybe, by uploading your brain at CNBC
02:54PM  LIVE: Sirius founder Martine Rothblatt @ eMerge at CNBC
May-01-15 01:34PM  Stocks Rebound Higher; Skyworks Finds Support At 50-Day Line at Investor's Business Daily +7.03%
01:04PM  UNITED THERAPEUTICS CORP Financials
06:53AM  United Therapeutics Corporation To Present At The Deutsche Bank 40th Annual Health Care Conference at noodls
06:00AM  United Therapeutics Corporation To Present At The Deutsche Bank 40th Annual Health Care Conference PR Newswire
Apr-30-15 08:13PM  10-Q for United Therapeutics Corp. at Company Spotlight
06:16AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Apr-29-15 12:08PM  [Podcast] Biogen is closing in on the holy grail for biotech stocks
09:42AM  United Therapeutics Falls on Q1 Loss, Misses on Revenues - Analyst Blog
Apr-28-15 06:50PM  Merck Jumps, United Therapeutics Drops On Q1 Earnings at Investor's Business Daily -5.17%
11:01AM  United Therapeutics' Q1 Sales Miss Hammers Stock at Investor's Business Daily
07:07AM  Q1 2015 United Therapeutics Corp Earnings Release - Before Market Open
06:13AM  United Therapeutics reports 1Q loss
06:10AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:10AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports First Quarter 2015 Financial Results PR Newswire
Apr-27-15 04:59PM  Will United Therapeutics (UTHR) Miss This Earnings Season? - Analyst Blog -7.75%
01:16PM  Biotechs Weigh On Nasdaq, But Apple, Twitter Hold Firm at Investor's Business Daily
Apr-26-15 08:02AM  4 Top-Rated Drugmakers Reporting Earnings This Week at Investor's Business Daily
Apr-23-15 04:57PM  Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog
Apr-22-15 07:48AM  Twitters latest shareholder slap: $73 million for a finance guy at MarketWatch
Apr-21-15 06:18AM  United Therapeutics Corporation To Announce First Quarter 2015 Financial Results Before Market Open On Tuesday, April 28, 2015 at noodls
06:00AM  United Therapeutics Corporation To Announce First Quarter 2015 Financial Results Before Market Open On Tuesday, April 28, 2015 PR Newswire
Apr-16-15 01:35PM  United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shahs Top Healthcare Picks Dominated S&P 500 Index in January-March at Insider Monkey
Mar-30-15 06:04PM  MedImmune, Tech Council of Maryland chart path for region's biotech community at bizjournals.com
Mar-27-15 04:11PM  Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks Amici Capital Is Bullish on at Insider Monkey
Mar-26-15 08:48AM  United Therapeutics (UTHR) Crumbles: Stock Falls by 6.5% - Tale of the Tape
Mar-25-15 10:03AM  Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)s 18% Spike at Insider Monkey -6.50%
Mar-19-15 03:15PM  Retrophin Soars on FDA Approval of Bile Acid Disorder Drug - Analyst Blog
11:12AM  Akorn, Inc. (AKRX), United Therapeutics Corporation (UTHR) Among Consonance Capitals Winning Bets in Healthcare at Insider Monkey
Mar-18-15 01:00PM  To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher at bizjournals.com
Mar-17-15 03:15PM  SteadyMed hopes to break Bay Area IPO lull with $68.4M offering this week at bizjournals.com
Mar-13-15 01:19PM  Watch these drug stocks Monday
08:46AM  These new meds could move stocks
Mar-12-15 09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Pharmacyclics, Amgen, United Therapeutics and Regeneron - Press Releases
07:27AM  United Therapeutics upgraded by Argus
Mar-11-15 05:40PM  United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog
Mar-10-15 06:47PM  United Therapeutics
03:17PM  United Therapeutics Wins FDA Nod, Priority Voucher at Investor's Business Daily
11:28AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
11:18AM  United Therapeutics Receives a Rare Pediatric Disease Priority Review Voucher following the Approval of Unituxin for Pediatric High-Risk Neuroblastoma PR Newswire
11:12AM  FDA Approves Unituxin (dinutuximab) for the Treatment of Pediatric High-Risk Neuroblastoma PR Newswire
10:29AM  FDA approves United Therapeutics' drug for treating cancer in children Reuters
Feb-26-15 07:08PM  10-K for United Therapeutics Corp. Company Spotlight
Feb-25-15 02:59PM  Stocks Mixed; United Therapeutics Jumps To New High at Investor's Business Daily
10:40AM  United Therapeutics Beats on Q4 Earnings & Revenues - Analyst Blog Zacks
06:00AM  United Therapeutics Corporation To Present At The Cowen And Company 35th Annual Healthcare Conference PR Newswire
Feb-24-15 06:17PM  Jazz Pharma Tops, But Stock Falls On Guidance Investor's Business Daily
11:58AM  United Therapeutics beats Street 4Q forecasts AP
10:04AM  United Therapeutics Blood Pressure Drug Lifts Q4 at Investor's Business Daily
07:07AM  Q4 2014 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:15AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report EDGAR Online
06:14AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:00AM  United Therapeutics Corporation Reports 2014 Fourth Quarter And Annual Financial Results PR Newswire
Feb-18-15 04:39PM  Wednesday's Market Recap Yahoo Finance Contributors
Feb-17-15 06:00AM  United Therapeutics Corporation To Announce Fourth Quarter And Annual 2014 Financial Results Before Market Open On Tuesday, February 24, 2015 PR Newswire
Feb-05-15 06:32PM  Hot Growth Stocks: What Sectors Lead 2015 Now? at Investor's Business Daily
Jan-16-15 06:44PM  Ulta Among IBD 50 Stocks Setting Up In Shaky Market at Investor's Business Daily
02:20PM  Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog Zacks
Jan-15-15 05:33PM  NetEase, Other Leading Stocks Break Out To New Highs at Investor's Business Daily
12:50PM  Biotech Stock United Therapeutics Tests New Buy Point at Investor's Business Daily
Jan-06-15 09:50PM  United Therapeutics Corporation To Present At 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
01:03PM  UPDATE: Barclays Initiates Coverage On United Therapeutics Benzinga
Jan-05-15 07:14PM  UPDATE: BTIG Initiates Coverage On United Therapeutics Benzinga
Dec-31-14 06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:00AM  United Therapeutics Announces Signing Of Agreement For New Remodulin Delivery System PR Newswire
Dec-24-14 11:48AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
11:26AM  United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin PR Newswire
Dec-19-14 05:20PM  United Therapeutics Lung Drug Keeps Going And Going at Investor's Business Daily
Dec-17-14 06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ EDGAR Online
06:00AM  United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change PR Newswire
Dec-11-14 11:48AM  Can United Therapeutics find a remedy for recent resistance? at Investor's Business Daily
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
Nov-26-14 05:40PM  Stock Market Today: Top Biotech Is Near Buy Point at Investor's Business Daily
Nov-13-14 06:44AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:00AM  Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors PR Newswire
Oct-30-14 08:08PM  10-Q for United Therapeutics Corp. Company Spotlight
07:59PM  Apple CEO publicly acknowledges that he's gay AP
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & Co-CEOJul 02Option Exercise30.755,547170,5705,787Jul 02 06:48 PM
DWEK RAYMONDDirectorJul 02Option Exercise31.173,00093,5103,000Jul 02 06:54 PM
CAUSEY CHRISTOPHERDirectorJul 02Option Exercise41.141,50061,7102,458Jul 02 07:01 PM
CAUSEY CHRISTOPHERDirectorJul 02Option Exercise48.111,50072,1652,458Jul 02 07:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOJul 02Sale169.645,547940,988240Jul 02 06:48 PM
DWEK RAYMONDDirectorJul 02Sale171.593,000514,7560Jul 02 06:54 PM
CAUSEY CHRISTOPHERDirectorJul 02Sale171.761,500257,647958Jul 02 07:01 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJun 30Option Exercise57.152,000114,3003,375Jul 01 10:06 AM
JEFFS ROGERPresident & Co-CEOJun 30Option Exercise57.1510,000571,50011,456Jun 30 08:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 29Option Exercise52.652,592136,4692,832Jun 29 05:00 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 29Sale172.862,592448,065240Jun 29 05:00 PM
JEFFS ROGERPresident & Co-CEOJun 25Option Exercise51.3710,000513,70011,456Jun 25 08:12 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 25Option Exercise32.379,662312,7855,787Jun 25 08:30 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 25Sale176.919,6621,709,325240Jun 25 08:30 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 24Option Exercise63.222,211139,7792,451Jun 24 06:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 24Sale179.682,211397,270240Jun 24 06:15 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJun 23Option Exercise57.154,000228,6005,375Jun 23 09:28 PM
JEFFS ROGERPresident & Co-CEOJun 23Option Exercise47.502,875136,5634,331Jun 23 09:45 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 22Option Exercise52.652,592136,4692,832Jun 22 05:51 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 22Sale188.642,592488,960240Jun 22 05:51 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 18Option Exercise32.379,662312,7855,787Jun 18 04:51 PM
SULLIVAN LOUIS WDirectorJun 18Option Exercise37.6845,0001,695,45030,000Jun 22 06:47 AM
MAHON PAUL AEVP & General CounselJun 18Option Exercise31.144,750147,91539,804Jun 18 08:50 PM
JEFFS ROGERPresident & Co-CEOJun 18Option Exercise51.3710,000513,70011,456Jun 18 08:56 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 18Sale185.729,6621,794,403240Jun 18 04:51 PM
SULLIVAN LOUIS WDirectorJun 18Sale185.6015,0002,783,9730Jun 22 06:47 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJun 16Option Exercise57.154,000228,6005,375Jun 16 09:43 PM
JEFFS ROGERPresident & Co-CEOJun 16Option Exercise47.5010,000475,00011,456Jun 16 09:52 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 15Option Exercise52.652,592136,4692,832Jun 16 09:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 15Sale185.152,592479,906240Jun 16 09:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 11Option Exercise32.379,662312,7855,787Jun 11 09:52 PM
JEFFS ROGERPresident & Co-CEOJun 11Option Exercise51.3710,000513,70011,456Jun 11 09:31 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 11Sale183.769,6621,775,493240Jun 11 09:52 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 10Option Exercise63.222,211139,7792,451Jun 11 08:44 AM
ROTHBLATT MARTINE AChairman & Co-CEOJun 10Sale180.872,211399,909240Jun 11 08:44 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJun 09Option Exercise57.154,000228,6005,375Jun 10 06:10 PM
JEFFS ROGERPresident & Co-CEOJun 09Option Exercise47.5010,000475,00011,456Jun 10 06:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 08Option Exercise181.342,592470,0432,832Jun 08 07:02 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 08Sale181.342,592470,043240Jun 08 07:02 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 04Option Exercise32.379,662312,7855,787Jun 04 06:40 PM
CAUSEY CHRISTOPHERDirectorJun 04Option Exercise48.111,50072,1652,458Jun 05 08:20 PM
JEFFS ROGERPresident & Co-CEOJun 04Option Exercise51.3710,000513,70011,456Jun 05 08:24 PM
DWEK RAYMONDDirectorJun 04Option Exercise31.173,00093,5103,000Jun 04 06:07 PM
CAUSEY CHRISTOPHERDirectorJun 04Option Exercise41.141,50061,7102,458Jun 04 06:14 PM
MAHON PAUL AEVP & General CounselJun 04Option Exercise33.146,000198,84041,054Jun 04 06:20 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 04Sale181.949,6621,757,889240Jun 04 06:40 PM
DWEK RAYMONDDirectorJun 04Sale181.363,000544,0950Jun 04 06:07 PM
CAUSEY CHRISTOPHERDirectorJun 04Sale181.291,500271,931958Jun 04 06:14 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 03Option Exercise63.222,211139,7792,451Jun 03 04:54 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 03Sale184.492,211407,910240Jun 03 04:54 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerJun 02Option Exercise57.154,000228,6005,375Jun 02 08:53 PM
JEFFS ROGERPresident & Co-CEOJun 02Option Exercise47.5010,000475,00011,456Jun 02 08:41 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 01Option Exercise52.652,592136,4692,832Jun 01 07:36 PM
ROTHBLATT MARTINE AChairman & Co-CEOJun 01Sale182.662,592473,454240Jun 01 07:36 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 28Option Exercise32.379,662312,7855,787May 28 09:48 PM
JEFFS ROGERPresident & Co-CEOMay 28Option Exercise51.3710,000513,70011,456May 28 09:25 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 28Sale180.889,6621,747,710240May 28 09:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 27Option Exercise63.222,211139,7792,451May 27 08:28 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 27Sale184.392,211407,696240May 27 08:28 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 26Option Exercise52.652,592136,4692,832May 26 08:07 PM
JEFFS ROGERPresident & Co-CEOMay 26Option Exercise47.5010,000475,00011,456May 26 08:19 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMay 26Option Exercise57.154,000228,6005,375May 26 08:26 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 26Sale182.642,592473,411240May 26 08:07 PM
JEFFS ROGERPresident & Co-CEOMay 21Option Exercise51.3710,000513,70011,456May 27 08:12 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 21Option Exercise32.379,662312,7855,787May 21 08:59 PM
MAHON PAUL AEVP & General CounselMay 21Option Exercise33.146,000198,84041,054May 26 07:05 AM
Thompson Tommy GDirectorMay 21Option Exercise51.771,50077,6551,500May 21 04:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 21Sale182.449,6621,762,687240May 21 08:59 PM
Thompson Tommy GDirectorMay 21Sale182.041,500273,0570May 21 04:15 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 20Option Exercise63.222,211139,7792,451May 20 09:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 20Sale182.802,211404,179240May 20 09:04 PM
JEFFS ROGERPresident & Co-CEOMay 19Option Exercise47.5010,000475,00011,456May 19 08:45 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMay 19Option Exercise57.154,000228,6005,375May 19 08:54 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 18Option Exercise52.652,592136,4692,832May 19 08:49 AM
ROTHBLATT MARTINE AChairman & Co-CEOMay 18Sale177.792,592460,823240May 19 08:49 AM
ROTHBLATT MARTINE AChairman & Co-CEOMay 13Option Exercise63.222,211139,7792,451May 13 05:58 PM
KURZWEIL RAYDirectorMay 13Option Exercise54.7711,250616,16311,250May 13 06:07 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 13Sale175.412,211387,826240May 13 05:58 PM
JEFFS ROGERPresident & Co-CEOMay 12Option Exercise47.5010,000475,00011,456May 13 05:21 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 11Option Exercise52.652,592136,4692,832May 11 06:24 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 11Sale179.552,592465,402240May 11 06:24 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 07Option Exercise32.379,662312,7855,787May 07 08:45 PM
CAUSEY CHRISTOPHERDirectorMay 07Option Exercise41.141,50061,7102,458May 07 08:50 PM
PATUSKY CHRISTOPHERDirectorMay 07Option Exercise41.145,000205,7005,000May 07 08:54 PM
MAHON PAUL AEVP & General CounselMay 07Option Exercise33.146,000198,84041,054May 07 08:58 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 07Sale169.869,6621,641,180240May 07 08:45 PM
CAUSEY CHRISTOPHERDirectorMay 07Sale167.941,500251,910958May 07 08:50 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 06Option Exercise63.222,211139,77933,095May 06 05:52 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 06Sale169.222,211374,13530,884May 06 05:52 PM
JEFFS ROGERPresident & Co-CEOMay 05Option Exercise47.505,000237,5006,456May 06 05:35 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 04Option Exercise53.3117,914954,97033,476May 04 05:16 PM
ROTHBLATT MARTINE AChairman & Co-CEOMay 04Sale169.812,592440,15030,884May 04 05:16 PM
CAUSEY CHRISTOPHERDirectorMay 01Option Exercise48.111,50072,1652,458May 04 04:54 PM
DWEK RAYMONDDirectorMay 01Option Exercise31.173,00093,5103,000May 01 07:44 PM
DWEK RAYMONDDirectorMay 01Sale159.583,000478,7450May 01 07:44 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 30Option Exercise32.379,662312,78521,109Apr 30 08:03 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 30Sale162.369,6621,568,75115,562Apr 30 08:03 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 29Option Exercise63.222,211139,77917,773Apr 29 08:25 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 29Sale164.292,211363,24315,562Apr 29 08:25 PM
JEFFS ROGERPresident & Co-CEOApr 28Option Exercise47.505,000237,5006,456Apr 29 04:28 PM